Chemical Probes logo
JNJ-7891118 | JNJ-7891118 : Negative Allosteric of GRIN2A
RATINGS:
Cellular Use: (2 reviews)

In Model Organisms: (2 reviews)
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download

Probe Summary

Targets Biochemical/Biophysical Potency Cellular Potency
GRIN2A
  • IC50:40 nM
  • Ki:78 nM
  • IC50:44 nM
Negative Allosteric
up to 1 µM
up to 10 uM

Selectivity

In Vitro Selectivity Assessment
Potency Assay Off-Target:
> 200 fold selectivity over other homomeric GluN2 family members: GRIN2B, GRIN2C, GRIN2D all IC50 > ...
In Vitro Selectivity Assessment
Potency Assay Off-Target:
Cerep panel (Receptors, Transporters, Ion-Channels) 77 targets at 10 µM: clean; Kinase panel (373 ta ...

Potency
Cellular
In Vitro

GRIN2A

Mode of Action: Negative Allosteric

Structure-Activity-Relationship data available? No

DOI Reference: 10.1021/acs.jmedchem.4c02751

In Vivo Validations

Mouse
Dose: 1 mg/Kg
Route of delivery: Intravenous
Plasma half life: 0.7 ± 0.1 h
Systemic clearance: 22.9 ± 3.2 mL.min/Kg
Cmax: 2039.5 ± 596.2 ng/mL
Area Under the Curve:: 726.5 ± 96.8 h*ng/mL
Volume of Distribution at Steady-State: 1.0 ± 0.1 L/Kg

DOI Reference: 10.1021/acs.jmedchem.4c02751

Dose: 5 mg/Kg
Route of delivery: Oral
Plasma half life: 0.9 ± 0.2 h
Cmax: 1430.0 ± 91.0 ng/mL
Tmax: 0.3 ± 0.1 h
Area Under the Curve:: 1732.0 ± 397.3 h*ng/mL
Bioavailability: 47.2 ± 10.5 %

DOI Reference: 10.1021/acs.jmedchem.4c02751

Dose: 5 mg/Kg
Route of delivery: Subcutaneous
Plasma half life: 0.9 ± 0.0 h
Cmax: 2042.0 ± 287.9 ng/mL
Tmax: 0.3 ± 0.1 h
Area Under the Curve:: 3521.5 ± 431.2 h*ng/mL
Bioavailability: 95.7 ± 11.7%

DOI Reference: 10.1021/acs.jmedchem.4c02751

Rat
Dose: 1 mg/Kg
Route of delivery: Intravenous
Plasma half life: 0.6 ± 0.0 h
Systemic clearance: 41.3 ± 4.3 mL/min/Kg
Cmax: 2069.7 ± 529.8 ng/mL
Area Under the Curve:: 404.6 ± 44.2 h*ng/mL
Volume of Distribution at Steady-State: 1.0 ± 0.1 L/Kg

DOI Reference: 10.1021/acs.jmedchem.4c02751

Dose: 5 mg/Kg
Route of delivery: Oral
Plasma half life: 1.0 ± 0.1 h
Cmax: 300.7 ± 28.0 ng/mL
Tmax: 0.3 ± 0.1 h
Area Under the Curve:: 563.0 ± 358.2 h*ng/mL
Bioavailability: 28.0 ± 17.6 h

DOI Reference: 10.1021/acs.jmedchem.4c02751

Dose: 5 mg/Kg
Route of delivery: Subcutaneous
Plasma half life: 0.7 ± 0.1 h
Cmax: 841.3 ± 121.0 ng/mL
Tmax: 0.5 ± 0.0 h
Area Under the Curve:: 1459.9 ± 28.0 h*ng/mL
Bioavailability: 72.2 ± 1.7%

DOI Reference: 10.1021/acs.jmedchem.4c02751

Negative Control Compounds

canSAR7437557
Notes: JNJ-77914993 (cpd 14): GRIN2A = 48 µM; GRIN2B, GRIN2C, GRIN2D all IC50 > 50 µM (FLIPR)

Chemical Information

Molecular Formula C19H16ClF2N5O2
SMILEs Cc1nc(C(=O)NCc2cccnc2)cnc1OCC(F)(F)c1cc(Cl)ccn1
InChI InChI=1S/C19H16ClF2N5O2/c1-12-18(29-11-19(21,22)16-7-14(20)4-6-24-16)26-10-15(27-12)17(28)25-9-13-3-2-5-23-8-13/h2-8,10H,9,11H2,1H3,(H,25,28)
Molecular weight 419.10 Da
AlogP 3.329220000000002
HBond acceptors 7
HBond donors 1
Atoms 45

References

Publications

Cross References

Expert Reviews

by SERP
(on 4 Oct 2025 )
Cellular Use Rating
In Model Organisms
( The reviewer did not leave any comments )
by SERP
(on 27 Oct 2025 )
Cellular Use Rating
In Model Organisms
Compound 12 is a potent and selective negative allosteric modulator (NAM) of the GluN2A-containing NMDA receptor, acting at the GluN1–GluN2A interface. It exhibits an IC₅₀ of 40 nM in a calcium flux assay...
Note: The Chemical Probes Portal only endorses compounds as chemical probes for use as specific and selective modulators of the proposed target if they receive three or more (3-4) stars. Read more about our evaluation criteria